Tamoxifen Citrate
Summary of product characteristics
Effective Time
20230928
Version
6
Spl Product Data Elements
Tamoxifen Citrate Tamoxifen Citrate TAMOXIFEN CITRATE TAMOXIFEN CARBOXYMETHYLCELLULOSE CALCIUM HYPROMELLOSES MAGNESIUM STEARATE MANNITOL POLYETHYLENE GLYCOL, UNSPECIFIED STARCH, CORN TITANIUM DIOXIDE WHITE TO OFF-WHITE ROUND 826 Tamoxifen Citrate Tamoxifen Citrate TAMOXIFEN CITRATE TAMOXIFEN CARBOXYMETHYLCELLULOSE CALCIUM HYPROMELLOSES MAGNESIUM STEARATE MANNITOL POLYETHYLENE GLYCOL, UNSPECIFIED STARCH, CORN TITANIUM DIOXIDE WHITE TO OFF-WHITE ROUND 827
Application Number
ANDA206694
Brand Name
Tamoxifen Citrate
Generic Name
Tamoxifen Citrate
Product Ndc
70771-1185
Product Type
HUMAN PRESCRIPTION DRUG
Route
ORAL
Package Label Principal Display Panel
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1184-1 in bottle of 100 tablets Tamoxifen Citrate Tablets USP, 10 mg Rx Only 100 tablets NDC 70771-1185-1 in bottle of 100 tablets Tamoxifen Citrate Tablets USP, 20 mg Rx Only 100 tablets tamoxifen tablets tamoxifen tablets
Spl Medguide
SPL MEDGUIDE
199 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.